Skip to content

Pain control in post-operative OSMF patients.

TransdermalFentanyl Patch Vs Non-Opoid Analgesia in Postoperative Oral Sub mucous Fibrosis Patients: A Randomized Control Trial"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016007
Enrollment
50
Registered
2018-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K135- Oral submucous fibrosis Health Condition 2: K135- Oral submucous fibrosis

Interventions

Intervention1: Transdermal Fentanyl Patch: Transdermal Fentanul patch in dosage of 12.5 to 50 microgram per hour that is changed after every 72 hours will be used for a total of 7 to 9 days depending

Sponsors

AIIMS Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient with mouth opening 2. Good physical and mental condition (ASA I ,II ) 3. Absence of infection or trauma prior to the surgery.

Exclusion criteria

Exclusion criteria: 1. Age 65 years. 2. Patients/with life threatening cardio-respiratory co-morbidities increasing risk of complication during GA likeprevious MI/under treatment for CAD,COPD patients, severe hepatic and renal impairment, patients with head injury (condition that increased amount of pressure in brain),opioid tolerant patients. 3. A history of allergy to the drugs used in the present study. 4. All pregnant and lactating females. 5. Alcohol or narcotics abusers. 6. Patients with ulcerative lesions or malignant lesions. 7. Patients with hypersensitivity to fentanyl. 8. Patients who are taking MAO inhibitors. 9. Patients who are taking drugs for migraines. 10. Patients who are taking anti-retroviral, antifungal drugs

Design outcomes

Primary

MeasureTime frame
1.Pain: Assessing Pain using Visual analogue scale (VAS) 2. Mouth Opening (Passive+Active) will be measured postoperatively with vernier calliper/scale Timepoint: 1,3,5,7,9,15 day 1,3 months

Secondary

MeasureTime frame
1. Quality of life 2. Patient co operationTimepoint: 1,3,5,7,9,15 day 1,3 months

Countries

India

Contacts

Public ContactNihadha PM

All India Institute of Medical Sciences

chaudhry_kirti@yahoo.com8003993889

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026